Patent · US Active

iRNA agents targeted to the Rho-A gene

US7772200B2 · kind B2 · utility

1Cited by

15References

5Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Juergen Soutschek · Kasendorf, DE
Pamela Tan · Kulmbach, DE
Anke Geick · Bayreuth, DE
Hans-Peter Vornlocher · Bayreuth, DE

Key dates

Filing date	Jul 21, 2006
Grant date	Aug 10, 2010
Priority date	—
Expiry date	Jul 21, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.